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MODELING ARTERIAL WALL DRUG CONCENTRATIONS
FOLLOWING THE INSERTION OF A DRUG-ELUTING STENT∗
SEAN MCGINTY† , SEAN MCKEE‡ , ROGER M. WADSWORTH§ , AND CHRISTOPHER
MCCORMICK¶
Abstract. A mathematical model of a drug-eluting stent is proposed. The model considers a
polymer region, containing the drug initially, and a porous region, consisting of smooth muscle cells
embedded in an extracellular matrix. An analytical solution is obtained for the drug concentration
both in the target cells and the interstitial region of the tissue in terms of the drug release concen-
tration at the interface between the polymer and the tissue. When the polymer region and the tissue
region are considered as a coupled system, it can be shown, under certain assumptions, that the
drug release concentration satisfies a Volterra integral equation which must be solved numerically in
general. The drug concentrations, both in the cellular and extracellular regions, are then determined
from the solution of this integral equation and used in deriving the mass of drug in the cells and
extracellular space.
Key words. drug-eluting stent, atherosclerosis, Laplace transforms, branch points, analytical
solution, Volterra integral equation
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1. Introduction. Coronary heart disease (CHD) is the main cause of death in
developed countries [32] and accounts for 18% of all deaths in the United States an-
nually [27]. CHD is characterized by a blockage or occlusion of one or more of the
arteries which supply blood to the heart muscle. This is due to atherosclerosis, a
complex progressive inflammatory disease [25], which leads to the buildup of fatty
plaque material near the inner surface of the arterial wall [29]. If left untreated,
this leads to episodes of chest pain (angina). Ultimately, the atherosclerotic plaque
is vulnerable to rupture, leading to the formation of a blood clot which blocks the
artery, causing a heart attack. Until relatively recently, bypass surgery was required.
However, in the majority of cases, this has now been replaced by inserting a small
metallic cage, called a stent, into the occluded artery to maintain blood flow. When
a stent is implanted into an artery, the endothelium is severely damaged. The con-
sequent inflammatory response and excessive proliferation and migration of smooth
muscle cells leads to the development of in-stent restenosis (ISR), a reocclusion of the
artery which is a significant limitation of bare metal stents. The introduction of drug-
eluting stents (DESs) significantly reduced the occurrence of ISR by releasing a drug
to inhibit smooth muscle cell proliferation. However, their use has been associated
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MODELING DRUG-ELUTING STENTS 2005
Fig. 1.1. A selection of stent designs.
Fig. 1.2. The illustration shows a cross-section of a coronary artery with plaque buildup. The
coronary artery is located on the surface of the heart. In A we see the deflated balloon catheter
inserted into the narrowed coronary artery. In B, the balloon is inflated, compressing the plaque
and restoring the size of the artery. Finally, C shows the widened artery. (Source: National Heart,
Lung, and Blood Institute; National Institutes of Health; U.S. Department of Health and Human
Services.)
with incomplete healing of the artery, and substantial eﬀorts are now dedicated to the
development of enhanced DESs. Photographs of typical stent designs are provided in
Figure 1.1, while Figure 1.2 displays the stent in situ in the coronary artery.
An important aspect in the performance of any DES is the drug release pro-
file. Although a number of animal models are recommended for preclinical safety
and eﬃcacy evaluation of these devices [38], incomplete understanding of the fac-
tors governing drug release and distribution following stenting currently limits the
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optimization of such drug release profiles. Several authors have focused specifically
on the drug release problem. Zhao et al. [45] presented an analytical solution of a cylin-
drical diﬀusion model to describe the experimental drug release of everolimus from a
Dynalink-E polymer coated stent. They demonstrated that the release could be con-
trolled by varying the coating thickness and diﬀusion coeﬃcient and found that their
model solution could be fitted to both in vitro and in vivo data simply by varying the
diﬀusion coeﬃcient. Formaggia, Minisini, and Zunino [15] considered a dissolution-
diﬀusion model which also incorporated polymer degradation, while Prabhu and Hus-
sainy [36] focused specifically on the degradation and release of everolimus from a
polylactic stent coating and validated their compartmentalized model using in vitro
data. A number of other contributions in the literature have attempted to combine
mathematical modeling with experimental validation. Balakrishnan et al. [2] utilized
computational fluid dynamics and two-dimensional transient convection-diﬀusion to
make predictions of drug elution which were then verified using empirical data from
stented porcine arteries. They found that arterial uptake was only maximized when
the rates of drug release and absorptions matched. Rossi et al. [37] modeled a biore-
sorbable DES based on detailed constitutive equations and taking into account the
main physical and chemical mechanisms involved in coating degradation, drug re-
lease, and restenosis inhibition. Their results were verified against selected in vitro
and in vivo data available in the literature. Most recently, Tzafriri et al. [42] developed
a mathematical framework of arterial drug distribution and receptor binding following
stent elution. Their model predicted that tissue content linearly tracked stent elu-
tion rate; this prediction was validated in porcine coronary artery sirolimus-eluting
polymer coated stent implants. In an attempt to make some gains in modeling this
complex problem, Seidlitz et al. [39] utilized a vessel-simulating flow through cell to
examine release from DES in vitro. This tool allowed for the examination of diﬀusion
depth and the distribution in the arterial wall.
Several computational approaches to drug release from stents have been employed.
Lovich and Edelman [28], Constantini, Maceri, and Vairo [10], and McGinty et al.
[30] numerically studied a one-dimensional model. Two-dimensional models were
computed by Hwang, Wu, and Edelman [20], Zunino [47], and Grassi et al. [16].
A three-dimensional model in a simplified geometry was studied by Hose et al. [19],
while Vairo et al. [43] considered a multidomain approach. Zunino et al. [48] presented
three-dimensional numerical models of stent expansion and release into the blood flow
and tissue, while the eﬀect of luminal flow on arterial deposition is considered in [23]
and [24]. Karner and Perktold [21] used the finite element method to calculate the
transport processes across the lumen, the intima, and the media, coupled with the flux
across the endothelium and the internal elastic lamina, which they modeled mathe-
matically using the Kedem–Katchalsky equations. Delfour, Garon, and Longo [14],
on the other hand, focused on the eﬀect of the number of struts and the ratio between
the coated area, and attempted to optimize the eﬀect of the dose. Mongrain et al.
[31] numerically investigated the eﬀect of diﬀusion coeﬃcient and struts apposition on
drug accumulation in the arterial wall. More recently, Tambacˇa et al. [41] presented a
mathematical model for the study of the mechanical properties of endovascular stents
in their expanded state. Realizing the sheer complexity of modeling the whole stent-
tissue system, D’Angelo et al. [13] employed model reduction strategies to simplify the
computations. This involved a combination of lumped parameter models to account
for drug release, a one-dimensional model to handle the complex stent pattern, and a
three-dimensional model for drug transfer in the artery.
Despite the aforementioned numerical advances, there is still a lack of analytical
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solutions in the literature, especially for the coupled stent-tissue system. Two inter-
esting papers by Pontrelli and de Monte [33], [34] considered a similar model to the
more general (but still one-dimensional) models of McGinty et al. [30]. Their model
is a two-layer model (drug concentration in both the polymer and the tissue regions)
and, through the Kedem–Katchalsky equations, allows for a topcoat. They obtained
an elegant analytical solution through separation of variables and used this solution
to show the eﬀect of filtration velocity, drug metabolism, and the amount (i.e., the
mass) of drug in the tissue. Pontrelli and de Monte have subsequently extended their
work to consider a multilayer model [35]. Mathematical models which admit analyt-
ical solutions, such as the one considered in this paper, have a real part to play in
addressing this complex problem.
This paper develops a mathematical model for drug release from polymer coated
DESs and the subsequent uptake into the arterial wall. Having written a model which
makes certain simplifying assumptions, the strategy is the following. First, we assume
that we know the drug release concentration at the interface between the polymer and
the tissue, say g(t). This allows us to obtain a general analytical solution for any g(t)
both for the drug concentration in the extracellular matrix and the smooth muscle cells
themselves. This analytical solution involves the inversion of a Laplace transform with
three branch points. We then examine the concentration in the polymer and observe
that, if g(t) were known, the problem would be over-determined. Indeed, we can
write two independent well-posed problems, both of which admit analytical solutions.
However, the arbitrary function g(t), representing drug release, must be such that the
two solutions are identical. Hence, by equating these two solutions, it is possible to
derive a Volterra integral equation for g(t). We then proceed to solve this integral
equation for g(t) and utilize this in computing the mass of drug in the cells and
extracellular space. Thus we have an alternative approach to the two-layered model
of Pontrelli and de Monte that is capable of modeling the drug concentration within
the target smooth muscle cells, which is what clinicians are principally interested in.
This is a novel approach to solving this problem and, moreover, can be regarded as a
generic mathematical tool for solving these types of diﬀusion systems.
2. The structure of the arterial wall. The arterial wall is a heterogeneous
structure consisting of three distinct layers: the intima, the media, and the adventitia
[44]; see Figure 2.1. The intima is the innermost region closest to the lumen. The
main constituent of the intima is the endothelial layer of cells, known as the endothe-
lium. This layer is crucial to the control of the normal function of the artery, through
its mediation of relaxation and contraction and via its control of smooth muscle cell
proliferation within the underlying media layer. The internal elastic lamina (a fenes-
trated layer of elastic tissue) forms the outermost part of the intima. The next layer
is the media (middle) region containing smooth muscle cells, collagen, and elastin.
Finally, the outermost layer of the arterial wall is the adventitia, which is separated
from the media by the external elastic lamina. Essentially, the adventitia tethers the
artery to perivascular tissue and contains cells known as fibroblasts. There is also the
presence of a network of small blood vessels, termed vasa vasorum, which act as a
blood supply to the adventitia and provide a clearance mechanism for drugs released
into the artery wall.
3. The mathematical model. To obtain a tractable mathematical model we
make certain assumptions about the structure of the arterial wall. The intima, when
it is devoid of the endothelium, has a structure similar to that of the media region,
and for this reason we shall not include the intima as a separate region in the model.
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Fig. 2.1. The structure of the arterial wall.
Fig. 3.1. Simplified geometry displaying stent impinged against media region containing smooth
muscle cells and extracellular space.
Second, the adventitia is omitted, since there is some evidence in the literature [30]
that the adventitia does not have a large eﬀect on the cellular drug concentration in
the media region. The media consists of two phases: one of smooth muscle cells, and
the other of collagen and elastin surrounded by an interstitial (or extracellular) region.
We treat the media as a porous region, where the porosity, φ ∈ (0, 1), is defined as
the ratio of the volume of interstitial space to the total volume. The drug is known
to have a partition coeﬃcient, K, that is, the equilibrium ratio of concentrations
of a compound in two diﬀerent phases, and we regard the drug as interacting with
the cells but not diﬀusing within them. It is well accepted (see, for example, [3])
that there is a transmural flow of plasma across the intima and through the media
causing the drug to convect. We shall assume that the velocity of this flow, v, is
constant. The purpose of including the drug within the stent is to target, and hence
inhibit, the smooth muscle cells which constitute the neointima. Figure 3.1 provides a
diagrammatic sketch of the simplified physiology of the artery wall. Of course, these
assumptions are somewhat gross, but they do have the advantage that they allow
some progress toward an analytical solution rather than a purely numerical one.
We consider a stent coated with a thin layer (of thickness L) of polymer con-
taining a drug and embedded into the arterial wall (of thickness L1) as schematically
illustrated in Figure 3.1. We introduce c1(x, t) and c2(x, t) which denote, respec-
tively, the concentration of the drug in the interstitial region (of the media) and the
concentration of the drug within the cells. The drug concentration in the polymer,
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MODELING DRUG-ELUTING STENTS 2009
c(x, t), is assumed to satisfy a diﬀusion equation with diﬀusion coeﬃcient D, while the
transport of drug through the media is governed by an advection-diﬀusion equation
where the transmural velocity of the plasma is denoted by v, and D1 denotes the drug
diﬀusion coeﬃcient through the interstitial region. We include an uptake equation,
with drug uptake rate constant α, to describe the uptake of drug into the cells within
the tissue. The mathematical model is
∂c
∂t
= D
∂2c
∂x2
, x ∈ (−L, 0), t > 0,(3.1)
D
∂c
∂x
= 0, x = −L, t > 0,(3.2)
c = c0, x ∈ [−L, 0], t = 0,(3.3)
D
∂c
∂x
= D1
∂c1
∂x
− vc1, x = 0, t > 0,(3.4)
−D ∂c
∂x
= P (c− c1), x = 0, t > 0,(3.5)
φ
∂c1
∂t
+ v
∂c1
∂x
= D1
∂2c1
∂x2
− α(c1 − c2/K), x ∈ (0, L1), t > 0,(3.6)
c1, c2 bounded, x ∈ [0, L1], t ∈ [0,∞),(3.7)
c1 = c2 = 0, x ∈ [0, L1], t = 0,(3.8)
(1− φ) ∂c2
∂t
= α(c1 − c2/K), x ∈ (0, L1), t > 0.(3.9)
This model assumes that the drug in the polymer is in a single phase which is per-
mitted to freely diﬀuse. This is appropriate when the initial concentration of drug
in the polymer is below solubility, in which case the dissolution of drug can be re-
garded as instantaneous [8]. If the initial concentration of drug in the polymer is
above solubility, then the drug may exist in two forms, crystalline and dissolved, with
only dissolved drug free to diﬀuse. An approximate solution to the problem of drug
release into an infinite sink for this case is provided by Higuchi [17]. Generalizations
of Higuchi’s work were considered by Biscari et al. [6] and Cohen and Erneux [9].
However, in some DES systems, it may well be the case that the initial concentration
of the drug in the polymer is above solubility. In this case, if diﬀusion is the governing
step in the release process, then our assumption is still valid [40]. In this paper we
focus on the polymer coated Cypher sirolimus-eluting stent (see section 6 for a de-
scription). We have conducted experiments within our laboratory which examine in
vitro drug release from the Cypher stent. Figure 3.2 displays a comparison between
the experimentally measured cumulative percentage of drug released and the widely
published solution of (3.1)–(3.3) along with the condition c = 0 at x = 0 (see, for
D
ow
nl
oa
de
d 
02
/2
7/
15
 to
 1
30
.1
59
.8
2.
28
. R
ed
ist
rib
ut
io
n 
su
bje
ct 
to 
SIA
M 
lic
en
se 
or 
co
py
rig
ht;
 se
e h
ttp
://w
ww
.si
am
.or
g/j
ou
rna
ls/
ojs
a.p
hp
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © by SIAM. Unauthorized reproduction of this article is prohibited. 
2010 S. MCGINTY, S. MCKEE, R. M. WADSWORTH, AND C. MCCORMICK
0 10 20 30 40 50 600
10
20
30
40
50
60
70
80
90
100
Release of sirolimus from the Cypher stent
Release Period (days)
Pe
rc
en
ta
ge
 o
f s
iro
lim
us
 re
le
as
ed
 
 
Model
Experiments
Fig. 3.2. Comparison between in vitro experimental data and diﬀusion-based model of sirolimus
release from the Cypher stent. Briefly, the experiments consisted of placing four Cypher DESs in
separate sealed glass vials containing physiological release medium (phosphate buﬀered saline:ethanol
(90:10)). The experiments were carried out at 37◦C. At several time points up to 60 days, each
stent was removed and placed in a separate vial containing fresh release medium, with the mass of
drug in the original solution subsequently quantified using UV spectroscopy.
example, Crank [12]). The good agreement between the model and the experiments
serves to demonstrate that diﬀusion is the dominant mechanism of release, at least
for this particular stent. The best-fitting value of D based on a least squares analysis
was found to be of the order 10−16m2s−1.
We assume that the polymer rests against the bare metal of the stent, and con-
sequently there is zero flux at x = −L. For simplicity the initial concentration within
the polymer is assumed to be some constant c0. At the polymer/tissue interface the
total flux is assumed to be continuous, and a topcoat on the polymer is allowed via
the condition (3.5) where, here, P denotes a parameter with units m s−1 (see, e.g.,
[33]). Equation (3.6) governs the movement of the drug in the interstitial region of
the media. Note that the “sink” term represents the removal of drug to the cells.
Some existing models consider binding sites within the tissue (see, e.g., [42], [7]). It
is certainly true that the drug will bind to binding sites in the tissue and in the cells
[42], [5], [26], although the strength of aﬃnity will likely vary substantially with the
particular drug under consideration, and further, it is not clear how the density of
the binding sites may be easily determined. The uptake of drug into smooth muscle
cells has been measured experimentally (see, for example, [46]). The model consid-
ered here does not account for binding sites in the extracellular matrix but instead
considers cells within the tissue absorbing and releasing drug as the concentration
in the extracellular region changes. This idea is supported by the work in [1] and
[18]. It is worth stating that no boundary condition has been stipulated at the me-
dia/adventitia interface. An argument could be made for imposing continuity of the
relative diﬀusive and convective fluxes across the interface, or simply that the extra-
cellular concentration falls to zero by the time the drug reaches the adventitia region.
These boundary conditions, and others, have been considered in the literature (see,
for example, [30], [47], [33]). However, in order to be able to obtain an analytical
solution, we do not state a boundary condition at x = L1, but instead impose the
condition that the concentration of drug in the extracellular region and the cells must
remain bounded for all x and t.
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MODELING DRUG-ELUTING STENTS 2011
Since the system is linear, one obvious approach would be to solve directly using
Laplace transforms. However, it is readily seen that this approach leads to a Laplace
transform which is simply impractical to invert. Further, any attempt to proceed
with the inversion would necessarily involve extremely complicated transcendental
equations that must be solved for the roots. Thus we consider the following novel
approach to solving this problem. Consider a simpler hypothetical problem where we
assume that we know c1(0, t) in terms of a general function of t, say g(t). This will
allow us to obtain the concentrations for the drug in both the cells and the interstitial
region (in terms of g(t)) and, as we shall see, reduce the problem of finding g(t) to
that of solving a Volterra integral equation.
We shall introduce the following nondimensional variables:
t′ = (D1/L
2
1)t, x
′ = x/L1, c
′ = c/c0, c
′
1 = c1/c0, c
′
2 = c2/c0,
so that the above model becomes (all primes have been omitted for reasons of clarity):
(3.1)′
∂c
∂t
= δ
∂2c
∂x2
, x ∈ (−ℓ, 0), t > 0,
(3.2)′
∂c
∂x
= 0, x = −ℓ, t > 0,
(3.3)′ c = 1, x ∈ [−ℓ, 0], t = 0,
(3.4)′ δ
∂c
∂x
=
∂c1
∂x
− Pe c1, x = 0, t > 0,
(3.5)′ − ∂c
∂x
= P˜ (c− c1), x = 0, t > 0,
(3.6)′ φ
∂c1
∂t
+ Pe
∂c1
∂x
=
∂2c1
∂x2
−Da(c1 − c2/K), x ∈ (0, 1), t > 0,
(3.7)′ c1, c2 bounded, x ∈ [0, 1], t > 0,
(3.8)′ c1 = c2 = 0, x ∈ [0, 1], t = 0,
(3.9)′ (1− φ)∂c2
∂t
= Da(c1 − c2/K), x ∈ (0, 1), t > 0.
Here δ = D/D1, ℓ = L/L1, P˜ = L1P/D, Pe = L1v/D1 (Peclet number), and
Da = L21α/D1 (Damkholer number).
4. An analytical solution. Consider the problem consisting of (3.6)′–(3.9)′
together with c1(0, t) = g(t). We shall now apply Laplace transforms to (3.6)
′ and
(3.9)′. We shall then discover, upon applying the complex inversion formula, that the
integrand has three branch points, requiring a modification of the usual Bromwich
contour and leading ultimately to an analytical solution in terms of the unknown drug
release concentration, g(t).
4.1. Solution in Laplace transform space. Rearranging (3.9)′ provides
∂c2
∂t
(x, t) +
γ
K
c2(x, t) = γc1(x, t),(4.1)
where
γ =
Da
1− φ.
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Solving (4.1) subject to the initial condition gives
c2(x, t) = γ
∫ t
0
e−γ(t−t
′)/K c1(x, t
′) dt′.(4.2)
After substituting (4.2) into (3.6)′, we obtain
φ
∂c1
∂t
(x, t) + Pe
∂c1
∂x
(x, t)(4.3)
=
∂2c1
∂x2
(x, t)−Da
(
c1(x, t)− γ
K
∫ t
0
e−γ(t−t
′)/K c1(x, t
′) dt′
)
.
Define the Laplace transform of ci(x, t) (i = 1, 2) with respect to t:
c¯i(x, s) =
∫ ∞
0
e−st ci(x, t) dt.
Now, taking Laplace transforms of (4.3) yields, after making use of the initial condition
and rearranging,
d2c¯1
dx2
(x, s) − Pedc¯1
dx
(x, s) − Γ(s)c¯1(x, s) = 0,(4.4)
where
Γ(s) =
φKs
(
s+ γK +
Da
φ
)
Ks+ γ
.(4.5)
Solving (4.4) subject to c1(0, t) = g(t) and the boundedness of c1(x, t), we obtain
c¯1(x, s) = g¯(s) exp
{
xPe
2
}
exp
{
−x
2
√
Pe2 + 4Γ(s)
}
,(4.6)
where g¯(s) =
∫∞
0
e−stg(t)dt. Using the definition of Γ(s) from (4.5), it is possible to
rewrite (4.6) in a more transparent form which clearly displays the dependence on s:
c¯1(x, s) = g¯(s) exp
{
xPe
2
}
exp
⎧⎨
⎩−x
√
φ
√
(s+ s1) (s+ s2)
s+ s3
⎫⎬
⎭,(4.7)
where
2s1,2 =
γ
K
+
Da
φ
+
Pe2
4φ
∓
√(
γ
K
+
Da
φ
+
Pe2
4φ
)2
− γPe
2
φK
,(4.8)
s3 =
γ
K
.(4.9)
Finally, taking the Laplace transform of (4.2) (and using convolution) allows us to
write the solution of c2 in Laplace transform space:
c¯2(x, s) =
γ
s+ s3
c¯1(x, s)(4.10)
=
γg¯(s)
(s+ s3)
exp
{
xPe
2
}
exp
⎧⎨
⎩−x
√
φ
√
(s+ s1) (s+ s2)
s+ s3
⎫⎬
⎭.D
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Fig. 4.1. Modified Bromwich contour. Note that the circles centered on −s1, −s3, and −s2
have radii ǫ1, ǫ3, and ǫ2, respectively. A,B, . . . ,N, O are defined in the appendix.
4.2. Solution via complex inversion formula. It will be convenient first to
determine the inverse of the Laplace transform
f¯(s) =
exp
{
−x√φ
√
(s+s1)(s+s2)
(s+s3)
}
s
;(4.11)
that is, by the complex inversion formula, we require
f(t) = L−1[f¯(s)] =
1
2πi
∫ β+i∞
β−i∞
exp
{
st− x√φ
√
(s+s1)(s+s2)
(s+s3)
}
s
ds.(4.12)
To evaluate (4.12) we consider the modified Bromwich contour in Figure 4.1. We
observe that the integrand of (4.12) has a simple pole at s = 0 and three branch
points at −s1,−s3, and −s2. We shall later demonstrate that the typical values of
the parameters characterizing the model are such that 0 < s1 < s3 < s2. Thus a
branch cut has been made along the negative real axis. The details of the inversion
are provided in the appendix. The solution f(t) turns out to be
f(t) = exp
{
−x
√
φs1s2
s3
}
− 1
π
(I1 + I˜1),(4.13)
where
I1 =
∫ ∞
s2
e−ut sin(a(u)x)
u
du, I˜1 =
∫ s3
s1
e−ut sin(a(u)x)
u
du,(4.14)
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with
a(u) =
√
φ(u − s1)(u − s2)
(u− s3) .(4.15)
Note that we can rewrite (4.7) as
c¯1(x, s) = exp
(
xPe
2
)
s g¯(s) f¯(s).(4.16)
An application of the convolution theorem to (4.16) and integration by parts results
in
(4.17)
c1(x, t) = exp
(
xPe
2
)⎡⎣g(t) exp
{
−x
√
φs1s2
s3
}
−
g(t)
(
I2 + I˜2
)
π
+
I3 + I˜3
π
⎤
⎦ ,
where
I2 =
∫ ∞
s2
sin(a(u)x)
u
du, I˜2 =
∫ s3
s1
sin(a(u)x)
u
du
and
I3 =
∫ ∞
s2
∫ t
0
g(t′)e−u(t−t
′) sin(a(u)x) dt′du,
I˜3 =
∫ s3
s1
∫ t
0
g(t′)e−u(t−t
′) sin(a(u)x) dt′du.
A further application of the convolution theorem to (4.11) then yields
c2(x, t) = γ exp
(
xPe
2
)[
exp
{
−x
√
φs1s2
s3
}
I4 − I5 + I˜5
π
+
I6 + I˜6
π
]
,(4.18)
where
I4 =
∫ t
0
g(t′)e−s3(t−t
′)dt′,
I5 =
∫ ∞
s2
∫ t
0
g(t′)e−s3(t−t
′) sin(a(u)x)
u
dt′du,
I˜5 =
∫ s3
s1
∫ t
0
g(t′)e−s3(t−t
′) sin(a(u)x)
u
dt′du
and
I6 =
∫ ∞
s2
∫ t
0
∫ τ
0
g(t′)e−u(τ−t
′)e−s3(t−τ) sin(a(u)x) dt′dτdu,
I˜6 =
∫ s3
s1
∫ t
0
∫ τ
0
g(t′)e−u(τ−t
′)e−s3(t−τ) sin(a(u)x) dt′dτdu.
D
ow
nl
oa
de
d 
02
/2
7/
15
 to
 1
30
.1
59
.8
2.
28
. R
ed
ist
rib
ut
io
n 
su
bje
ct 
to 
SIA
M 
lic
en
se 
or 
co
py
rig
ht;
 se
e h
ttp
://w
ww
.si
am
.or
g/j
ou
rna
ls/
ojs
a.p
hp
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © by SIAM. Unauthorized reproduction of this article is prohibited. 
MODELING DRUG-ELUTING STENTS 2015
5. A Volterra integral equation. We have obtained c1(x, t) and c2(x, t) in
terms of the arbitrary function g(t). The object now is to determine g(t). Consider
the problem
∂c
∂t
= δ
∂2c
∂x2
, x ∈ (−ℓ, 0), t > 0,(5.1)
∂c
∂x
= 0, x = −ℓ, t > 0,(5.2)
c = 1, x ∈ [−ℓ, 0], t = 0,(5.3)
δ
∂c
∂x
=
∂c1
∂x
− Pe c1, x = 0, t > 0,(5.4)
− ∂c
∂x
= P˜ (c− c1), x = 0, t > 0,(5.5)
where we intend to replace c1(0, t) by g(t). If we were able to determine ∂c1(0, t)/∂x
(and hence ∂c(0, t)/∂x), then (5.1)–(5.5) would be overdetermined. This “over-
determinedness” could then be used to find an expression for g(t). However, it is
not diﬃcult to see that ∂c1(0, t)/∂x is not defined: this is a direct consequence of
the discontinuity in the boundary and initial condition at x = 0 and t = 0 of the
model defined by (3.1)–(3.9). A form of regularization is required. We have chosen
to approximate ∂c1(0, t)/∂x by utilizing the solution of the corresponding problem of
pure diﬀusion in a semi-infinite composite region. To be precise here, we mean the
solution obtained by solving (3.1)′–(3.7)′, where [0, 1] has been replaced by [0,∞),
φ = 1, and Pe and Da have been taken to be zero. It can be readily shown that, in
this case,
∂c1(0, t)
∂x
=
P˜
√
δ
π
∫ ∞
0
B sin
(
l
√
u/δ
)
exp (−ut)
√
u (A2 +B2)
du,
= j(t), say,
where
A = P˜ cos
(
l
√
u/δ
)
−
(√
u/δ
)
sin
(
l
√
u/δ
)
and
B = P˜
√
δ sin
(
l
√
u/δ
)
.
Thus, we regularize by replacing (5.4) by
δ
∂c
∂x
= j(t)− Pe c1, x = 0, t > 0.(5.6)
Consider the further transformation of the independent variables
t′ = (δ/ℓ2)t, x′ =
(
x+ ℓ
ℓ
)
,(5.7)
so that (5.1)–(5.3), (5.5), and (5.6) become
∂c
∂t
=
∂2c
∂x2
, x ∈ (0, 1), t > 0,(5.8)
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∂c
∂x
= 0, x = 0, t > 0,(5.9)
c = 1, x ∈ [0, 1], t = 0,(5.10)
∂c
∂x
=
ℓ
δ
j(t)− ℓPe
δ
g(t), x = 1, t > 0,(5.11)
− ∂c
∂x
= P ∗(c− g(t)), x = 1, t > 0,(5.12)
where P ∗ = ℓP˜ = LP/D. Again, the primes have been omitted for clarity. We are
now in a position to write two problems and their associated solutions.
Problem 1.
∂c
∂t
=
∂2c
∂x2
, x ∈ (0, 1), t > 0,(5.13)
∂c
∂x
= 0, x = 0, t > 0,(5.14)
c = 1, x ∈ [0, 1], t = 0,(5.15)
∂c
∂x
=
ℓ
δ
j(t)− ℓPe
δ
g(t), x = 1, t > 0.(5.16)
The following solution may be obtained from either an application of Laplace trans-
forms or separation of variables with Duhamel’s theorem:
c(x, t) = 1− ℓ
δ
∫ t
0
(Pe g(τ)− j(τ))(5.17) [
1 + 2
∞∑
n=1
(−1)n exp(−n2π2(t− τ)) cos(nπx)
]
dτ.
Problem 2.
∂c
∂t
=
∂2c
∂x2
, x ∈ (0, 1), t > 0,(5.18)
∂c
∂x
= 0, x = 0, t > 0,(5.19)
c = 1, x ∈ [0, 1], t = 0,(5.20)
−∂c
∂c
= P ∗(c− g(t)), x = 1, t > 0.(5.21)
In a similar manner the following solution may be obtained:
c(x, t) = 2P ∗
∞∑
n=0
exp(−ξ2nt) cos(ξnx)
ξn[(1 + P ∗) sin ξn + ξn cos ξn]
+ 2P ∗
∫ t
0
g(τ)
∞∑
n=0
ξn exp(−ξ2(t− τ)) cos(ξnx)
[(1 + P ∗) sin ξn + ξn cos ξn]
dτ,(5.22)
where ξn, n = 0, 1, 2, . . . , are the countably infinite roots of
ξ tan ξ = P ∗.(5.23)
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The two solutions (5.17) and (5.22) must be identical, i.e., valid for all values of
x ∈ [0, 1] and t > 0. We shall elect to equate the two integrals (over x) of (5.17)
and (5.22). The physical significance of this is that we are eﬀectively equating the
respective expressions for the mass of drug on the stent. Thus
2P ∗
∞∑
n=0
exp(−ξ2n t)
ξn[(1 + P ∗) sin ξn + ξn cos ξn]
∫ 1
0
cos(ξn x)dx
+ 2P ∗
∫ t
0
g(τ)
∞∑
n=0
ξn exp(−ξ2n(t− τ))
[(1 + P ∗) sin ξn + ξn cos ξn]
∫ 1
0
cos(ξn x)dx dτ
= 1− ℓ
δ
∫ t
0
(Pe g(τ)− j(τ))
[
1 + 2
∞∑
n=1
(−1)n exp(−n2π2(t− τ))
∫ 1
0
cos(nπx)dx
]
dτ,
and so
2P ∗
∞∑
n=0
exp(−ξ2n t) sin ξn
ξ2n[(1 + P
∗) sin ξn + ξn cos ξn]
+ 2P ∗
∫ t
0
g(τ)
∞∑
n=0
exp(−ξ2n(t− τ)) sin ξn
[(1 + P ∗) sin ξn + ξn cos ξn]
dτ
= 1− ℓ
δ
∫ t
0
(Pe g(τ)− j(τ)) dτ.
(5.24)
Diﬀerentiating with respect to t gives
−2P ∗
∞∑
n=0
exp(−ξ2n t) sin ξn
[(1 + P ∗) sin ξn + ξn cos ξn]
+ 2P ∗
(
g(t)
∞∑
n=0
sin ξn
[(1 + P ∗) sin ξn + ξn cos ξn]
−
∫ t
0
g(t)
∞∑
n=0
ξ2n exp(−ξ2n(t− τ)) sin ξn
[(1 + P ∗) sin ξn + ξn cos ξn]
dτ
)
(5.25)
= − ℓ
δ
(Pe g(t)− j(t)) .
Rearranging yields
{
2P ∗
∞∑
n=0
sin ξn
[(1 + P ∗) sin ξn + ξn cos ξn]
+
ℓPe
δ
}
g(t)
=
∫ t
0
{
2P ∗
∞∑
n=0
ξ2n exp(−ξ2n(t− τ)) sin ξn
[(1 + P ∗) sin ξn + ξn cos ξn]
}
g(τ)dτ
+ 2P ∗
∞∑
n=0
exp(−ξ2n t) sin ξn
[(1 + P ∗) sin ξn + ξn cos ξn]
+
ℓ
δ
j(t).
(5.26)
Solving this integral equation for g(t) allows us to determine c1(x, t) and c2(x, t)
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Table 6.1
Table of parameter values based on McGinty et al. [30], Tzafriri et al. [42], and Pontrelli and
de Monte [33], [34].
Parameter Symbol Value
Media porosity φ 0.61
Media thickness L1 4.5× 10−4m
Media diﬀusion coeﬃcient D1 2.5× 10−10m2s−1
Drug uptake rate constant α 2× 10−5s−1
Partition coeﬃcient K 15
Transmural velocity v 5.8× 10−8ms−1
Polymer diﬀusion coeﬃcient D 10−16m2s−1
Permeability of topcoat P 10−8ms−1
Polymer thickness L 1.26× 10−5m
through the analytical solutions obtained in section 4. The concentration of drug
within the polymer may then be obtained from either (5.17) or (5.22).
6. Parameter values. A common diﬃculty when modeling physiological pro-
cesses is in obtaining estimates of the model parameters. Experimentation is often
prohibitively expensive or simply not possible in vivo, and it is therefore usual to draw
data from diﬀerent studies in the literature. We refer the reader to [30], where an
extensive literature search was performed to obtain estimates of the various param-
eters associated with drug elution from stents into arterial tissue. In this paper we
will consider the nonerodible polymer coated Cypher sirolimus-eluting stent. We have
chosen this particular stent system because it contains a drug-filled polymer coating
and the mechanism of release is generally accepted to be diﬀusion. Thus this stent
is well suited to our modeling assumptions. The Cypher stent coating is a blend of
polyethylene-co-vinyl acetate (PEVA), poly-n-butyl methacrylate (PBMA), and the
drug sirolimus. The coating is applied on a poly-o-chloro-p-xylylene (parylene-C)
treated stainless steel stent. The manufacture of the Cypher consists of applying
a basecoat solution containing PEVA, PBMA, and the drug. An inactive topcoat
and toulene spray are then applied. As a result of the mixing and drying process,
the drug is actually transported to the topcoat layer so that the drug-free topcoat is
never actually realized [4]. Most of the newer generation stents also make use of limus
compounds [22]. To consider diﬀerent compounds in our model, we would simply re-
quire measurements of the drug-dependent parameters. The value of media porosity
is taken directly from [30]. The polymer thickness is taken from [11] and the diﬀusion
coeﬃcient of sirolimus in the Cypher stent has been measured in our laboratory to be
of order 10−16m2s−1, while the values of the media diﬀusion coeﬃcient of sirolimus,
media thickness, and transmural velocity have been taken from [42]. The value of the
parameter P has been taken from [33], while the values of the drug uptake constant
and partition coeﬃcient of sirolimus have been estimated based on [30]. Using the pa-
rameter values in Table 6.1, we find that s1 = 3.7010×10−4, s2 = 0.0334, s3 = 0.0028
to four decimal places, satisfying 0 < s1 < s3 < s2.
7. Solution of the integral equation. Consider the discretization {tm =
mh, h = T/M,m = 0, 1, . . . ,M} and the associated vector (g0, g1, . . . , gm)
approximating (g(0), g(t1), . . . , g(tm)). We employ an explicit Euler-type method,
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2P ∗
∞∑
n=0
sin ξn
[(1 + P ∗) sin ξn + ξn cos ξn]
+
ℓPe
δ
}
gm
= h
m−1∑
j=0
{
2P ∗
∞∑
n=0
ξ2n exp(−ξ2n(m− j)h) sin ξn
[(1 + P ∗) sin ξn + ξn cos ξn]
}
gj(7.1)
+ 2P ∗
∞∑
n=0
exp(−ξ2nmh) sin ξn
[(1 + P ∗) sin ξn + ξn cos ξn]
+
ℓ
δ
Wm,
with
g0 = g(0) =
2P ∗Ψ(ξ) + ℓW0/δ
2P ∗Ψ(ξ) + ℓPeδ
,(7.2)
where
Ψ(ξ) =
∞∑
n=0
sin ξn
[(1 + P ∗) sin ξn + ξn cos ξn]
.
Before the discrete equation (7.1) can be solved, the roots of ξ tan ξ = P ∗ are required.
These have been obtained using a bisection approach. The infinite sums in (7.1) were
truncated after the first 20 terms and then, using the calculated roots, the finite
diﬀerence equation (7.1) was solved. Figure 7.1 displays g(t) = c1(0, t) over the first
day.
Now that g(t) has been obtained, we can utilize this g(t) in solution (4.17) and
(4.18) to obtain the concentration of drug in the extracellular and cellular regions,
and these are displayed in Figures 7.2 and 7.3.
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Fig. 7.1. g(t) = c1(0, t) over the first day as calculated from (5.26).
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Fig. 7.2. Variation in extracellular concentration with time, subject to g(t) obtained from the
solution of the Volterra integral equation.
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Fig. 7.3. Variation in cellular concentration with time, subject to g(t) obtained from the solution
of the Volterra integral equation.
8. Drug mass within the tissue. The total mass of drug in the media re-
gion at time t is given by integrating the expressions for cellular and extracellular
concentration over the length of the media. In nondimensional terms, this equates to
M(t) =
∫ 1
0
φ c1(x, t) dx+
∫ 1
0
(1− φ) c2(x, t) dx.(8.1)
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Fig. 8.1. Variation in mass of drug in the media with time, subject to g(t) obtained from the
solution of the Volterra integral equation.
Again, for convenience, the primes are suppressed.
Figure 8.1 displays the variation in mass of drug within the tissue over a period
of 10 days following stent deployment, using high-order global adaptive quadrature to
evaluate the integrals. We see that most of the mass is contained within the cells, due
to the high partition coeﬃcient of the drug. We have made two further assumptions
in producing these plots. First, it is assumed that all of the drug is eluted from the
stent, i.e., no drug is retained within the polymer. There is some evidence in the
literature that for some drug-eluting stents, not all of the drug is eluted, and in fact
some of the drug remains trapped in the stent. An example of such a stent is the
paclitaxel-eluting Taxus stent, which is also a polymer coated stent. Experiments
in our laboratory have revealed that for the sirolimus coated Cypher stent, at least
99% of the drug is eluted in vitro within the first three months, which justifies this
assumption. The second assumption is that all of the drug released from the stent
diﬀuses into the tissue. This assumption may be reasonable when the stent protrudes
into the arterial wall.
9. Concluding remarks. In this paper we have developed analytical solutions
for release of a drug from a polymer coated stent into the arterial wall. By assuming
initially that the drug release concentration at the polymer/tissue interface, g(t), is
known, we have been able to derive a Volterra integral equation, which allows us to
consider g(t) as a variable of our model. Upon solving the integral equation for g(t),
we have been able to determine the drug concentration profiles in the extracellular
and cellular regions of the arterial wall. Furthermore, we have calculated the mass of
drug in each region over the period of release.
We feel it appropriate to comment on the limitations of our model. We have con-
sidered a one-dimensional model which, while making it diﬃcult to generate quanti-
tative results, nonetheless allows us to obtain qualitative results. However, primarily
due to the regularization, there is a negligible amount of mass loss. Furthermore,
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the model assumes that the main mechanism of release is diﬀusion. The problem of
modeling arterial stents is very much an active field of research. The process of drug
release from the stent in vitro is still not fully understood, let alone the complex in
vivo situation where flowing blood, pulsatility, wound healing, proliferation, migra-
tion of cells, and complex uptake/binding no doubt all play some part. While we
do not claim to have addressed all these issues, we believe that simple models which
can admit analytical solutions, such as the one presented here, have a part to play in
addressing this complex problem.
Appendix. Solution via complex inversion formula. Consider the following
integral:
f(t) =
1
2πi
∫ β+i∞
β−i∞
exp
{
st− x√φ
√
(s+s1)(s+s2)
s+s3
}
s
ds
=
1
2πi
∫ β+i∞
β−i∞
estf¯(s)ds.(A.1)
To evaluate (A.1), consider the modified Bromwich contour in Figure 4.1. Notice that
the integrand of (A.1) has a simple pole at s = 0 and three separate branch points at
−s1, −s3, and −s2. For the parameter values considered, it is always the case that
0 < s1 < s3 < s2. Thus a branch cut has been made along the negative real axis (see
Figure 4.1).
Now,
1
2πi
∮
C
estf¯(s)ds
=
1
2πi
∫
AB
estf¯(s)ds+
1
2πi
∫
BC
estf¯(s)ds+
1
2πi
∫
CD
estf¯(s)ds
+
1
2πi
∫
DE
estf¯(s)ds+
1
2πi
∫
EF
estf¯(s)ds+
1
2πi
∫
FG
estf¯(s)ds
+
1
2πi
∫
GH
estf¯(s)ds+
1
2πi
∫
HJ
estf¯(s)ds+
1
2πi
∫
JK
estf¯(s)ds
+
1
2πi
∫
KL
estf¯(s)ds +
1
2πi
∫
LM
estf¯(s)ds+
1
2πi
∫
MN
estf¯(s)ds
+
1
2πi
∫
NO
estf¯(s)ds+
1
2πi
∫
OA
estf¯(s)ds
= Res(s = 0)(A.2)
so that there are 15 integrals to consider. It can be readily shown that as R → ∞,
the integrals over BC and OA vanish.
Along CD, let s = u eiθ, θ = π, s+ s1 = u1 e
iθ1 , θ1 = π, s+ s2 = u2 e
iθ2 , θ2 = π,
s+ s3 = u3 e
iθ3 , θ3 = π, from s = −R to s = −s2 − ǫ2:
1
2πi
∫
CD
estf(s)ds
=
1
2πi
∫ −s2−ǫ2
−R
estf(s)ds
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=
1
2πi
∫ ǫ2+s2
R
exp
{
−ut− x√φ
√
u1eipiu2eipi
u3eipi
}
−u (−du)
=
1
2πi
∫ ǫ2+s2
R
exp
{
−ut− ix√φ
√
u1u2
u3
}
u
du,
=
1
2πi
∫ ǫ2+s2
R
exp
{
−ut− ix√φ
√
(u−s1)(u−s2)
u−s3
}
u
du.(A.3)
Along DE, the point −s2 is moved to the origin by writing s = ǫ2eiθ − s2,
ds = iǫ2e
iθdθ. Thus,
1
2πi
∫
DE
estf(s)ds
=
ǫ2
2π
∫ 0
π
exp
{(
ǫ2e
iθ − s2
)
t− x√φ√ǫ2eiθ/2
√
ǫ2eiθ+s1−s2
ǫ2eiθ−s2+s3
+ iθ
}
ǫ2eiθ − s2 dθ
→ 0 as ǫ2 → 0.(A.4)
Along EF , let s = u eiθ, θ = π, s+ s1 = u1 e
iθ1 , θ1 = π, s+ s2 = u2 e
iθ2 , θ2 = 0,
s+ s3 = u3 e
iθ3 , θ3 = π, from s = −s2 + ǫ2 to s = −s3 − ǫ3:
1
2πi
∫
EF
estf(s)ds
=
1
2πi
∫ −s3−ǫ3
−s2+ǫ2
estf(s)ds
=
1
2πi
∫ s3+ǫ3
s2−ǫ2
exp
{
−ut− x√φ
√
(u−s1)(s2−u)
u−s3
}
u
du.(A.5)
Along FG, the point −s3 is moved to the origin by writing s = ǫ3eiθ − s3,
ds = iǫ3e
iθdθ. Thus,
1
2πi
∫
FG
estf(s)ds
=
ǫ3
2π
∫ 0
π
exp
{ (
ǫ3e
iθ − s3
)
t
−x
√
φ
ǫ3
e−iθ/2
√
(ǫ3eiθ + s1 − s3) (ǫ3eiθ − s3 + s2) + iθ
}
ǫ3eiθ − s3 dθ
→ 0 as ǫ3 → 0.
(A.6)
Along GH , let s = u eiθ, θ = π, s+ s1 = u1 e
iθ1 , θ1 = π, s+ s2 = u2 e
iθ2 , θ2 = 0,
s+ s3 = u3 e
iθ3 , θ3 = 0, from s = −s3 + ǫ3 to s = −s1 − ǫ1:
1
2πi
∫
GH
estf(s)ds
=
1
2πi
∫ −s1−ǫ1
−s3+ǫ3
estf(s)ds
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=
1
2πi
∫ s1+ǫ1
s3−ǫ3
exp
{
−ut− ix√φ
√
(u−s1)(s2−u)
s3−u
}
u
du.(A.7)
Along HJ , the point −s1 is moved to the origin by writing s = ǫ1eiθ − s1,
ds = iǫ1e
iθdθ. Thus
1
2πi
∫
HJ
estf(s)ds
=
ǫ1
2π
∫ −π
π
exp
{(
ǫ1e
iθ − s1
)
t− x√φ√ǫ1eiθ/2
√
ǫ1eiθ−s1+s2
ǫ1eiθ−s1+s3
+ iθ
}
ǫ1eiθ − s1 dθ
→ 0 as ǫ1 → 0.(A.8)
Along JK, let s = u eiθ, θ = −π, s + s1 = u1 eiθ1 , θ1 = −π, s + s2 = u2 eiθ2 ,
θ2 = 0, s+ s3 = u3 e
iθ3 , θ3 = 0, from s = −s1 − ǫ1 to s = −s3 + ǫ3:
1
2πi
∫
JK
estf(s)ds
=
1
2πi
∫ −s3+ǫ3
−s1−ǫ1
estf(s)ds
=
1
2πi
∫ s3−ǫ3
s1+ǫ1
exp
{
−ut+ ix√φ
√
(u−s1)(s2−u)
s3−u
}
u
du.(A.9)
Along KL, the point −s3 is moved to the origin by writing s = ǫ3eiθ − s3,
ds = iǫ3e
iθdθ. Thus,
1
2πi
∫
KL
estf(s)ds
=
ǫ3
2π
∫ −π
0
exp
{ (
ǫ3e
iθ − s3
)
t
−x
√
φ
ǫ3
e−iθ/2
√
(ǫ3eiθ + s1 − s3) (ǫ3eiθ − s3 + s2) + iθ
}
ǫ3eiθ − s3 dθ
→ 0 as ǫ3 → 0.
(A.10)
Along LM , let s = u eiθ, θ = −π, s + s1 = u1 eiθ1 , θ1 = −π, s + s2 = u2 eiθ2 ,
θ2 = 0, s+ s3 = u3 e
iθ3 , θ3 = −π, from s = −s3 − ǫ3 to s = −s2 + ǫ2:
1
2πi
∫
LM
estf(s)ds
=
1
2πi
∫ −s2+ǫ2
−s3−ǫ3
estf(s)ds
=
1
2πi
∫ s2−ǫ2
s3+ǫ3
exp
{
−ut− x√φ
√
(u−s1)(s2−u)
u−s3
}
u
du.(A.11)
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Along MN , the point −s2 is moved to the origin by writing s = ǫ2eiθ − s2,
ds = iǫ2e
iθdθ. Thus
1
2πi
∫
MN
estf(s)ds
=
ǫ2
2π
∫ −π
0
exp
{(
ǫ2e
iθ − s2
)
t− x√φ√ǫ2eiθ/2
√
ǫ2eiθ+s1−s2
ǫ2eiθ−s2+s3
+ iθ
}
ǫ2eiθ − s2 dθ
→ 0 as ǫ2 → 0.(A.12)
Along NO, let s = u eiθ, θ = −π, s + s1 = u1 eiθ1 , θ1 = −π, s + s2 = u2 eiθ2 ,
θ2 = −π, s+ s3 = u3 eiθ3 , θ3 = −π, from s = −s2 − ǫ2 to s = −R:
1
2πi
∫
NO
estf(s)ds
=
1
2πi
∫ −R
−s2−ǫ2
estf(s)ds
=
1
2πi
∫ R
s2+ǫ2
exp
{
−ut+ ix√φ
√
(u−s1)(u−s2)
u−s3
}
u
du.(A.13)
Now, the residue at the simple pole s = 0 is
lim
s→0
s exp
{
st− x√φ
√
(s+s1)(s+s2)
s+s3
}
s
= exp
{
−x
√
φs1s2
s3
}
.(A.14)
By the residue theorem,
1
2πi
∮
C
estf(s)ds = exp
{
−x
√
φs1s2
s3
}
.(A.15)
Hence, with the integrals along BC, DE, FG, HJ , KL,MN , and OA tending to zero
in the limit, and with the integrals along EF and LM cancelling through addition,
the only contributions are those from the integrals along CD, GH , JK, and NO.
Thus, (A.2) reduces to
1
2πi
∫
AB
estf(s)ds
= exp
{
−x
√
φs1s2
s3
}
− 1
2πi
lim
R→∞,ǫ1,2,3→0
⎧⎨
⎩
∫
CD
estf(s)ds+
∫
GH
estf(s)ds
+
∫
JK e
stf(s)ds+
∫
NO e
stf(s)ds
⎫⎬
⎭
= exp
{
−x
√
φs1s2
s3
}
− 1
π
⎧⎪⎪⎨
⎪⎪⎩
∫∞
s2
e−ut
u sin
(
x
√
φ
√
(u−s1)(u−s2)
u−s3
)
du
+
∫ s3
s1
e−ut
u sin
(
x
√
φ
√
(u−s1)(s2−u)
s3−u
)
du
⎫⎪⎪⎬
⎪⎪⎭ .(A.16)
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The solutions for c1 and c2 follow directly from (A.16) using convolution.
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